DCM
MGNX icon

Delpha Capital Management’s MacroGenics MGNX Stock Holding History

Delpha Capital Management’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-873
Closed -$17K – 779
2017
Q4 		$17K Buy
+873
New +$16.3K 0.02% 855

Other funds holding MGNX

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Delpha Capital Management's MGNX Position: Q1 2018 in Review

Delpha Capital Management sold out of MacroGenics (MGNX) in Q1 2018, closing a stake of 873 shares — an estimated $17K sold.

Delpha Capital Management first reported a position in MGNX in Q4 2017 and held it in 1 quarter. The position peaked at $17K in Q4 2017. 132 funds tracked by Wall St. Rank hold MGNX as of Q1 2018.

  • Delpha Capital Management reported no remaining MacroGenics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 873 MacroGenics shares in Q1 2018, an estimated $17K.
  • Delpha Capital Management first reported a position in MacroGenics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's MacroGenics position peaked at $17K in Q4 2017.
  • 132 funds tracked by Wall St. Rank held MacroGenics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.